|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:rifampin
gptkb:clarithromycin
gptkb:ritonavir
gptkb:carbamazepine
gptkb:ketoconazole
gptkb:St._John's_Wort
|
|
gptkbp:eliminationHalfLife
|
5-9 hours (young), 11-13 hours (elderly)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
GQSPXLAQXDMGEX-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:hasPharmacodynamics
|
inhibits free and clot-bound Factor Xa
|
|
gptkbp:hasSMILES
|
CC1=NN(C2=C1C=CC(=C2)Cl)C(=O)C3=CC=C(C=C3)S(=O)(=O)NC(=O)O
|
|
gptkbp:hasUNII
|
Y6O7T4G8P9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB06228
|
|
gptkbp:indication
|
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of recurrent DVT and PE
prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
prevention of venous thromboembolism in patients undergoing knee or hip replacement surgery
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Bayer
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
direct Factor Xa inhibitor
|
|
gptkbp:metabolism
|
hepatic (CYP3A4, CYP2J2, CYP-independent mechanisms)
|
|
gptkbp:molecularWeight
|
435.88
|
|
gptkbp:name
|
gptkb:Rivaroxaban
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2010604
gptkb:DB06228
9875401
D08917
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
dyspepsia
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:target
|
gptkb:Factor_Xa
|
|
gptkbp:bfsParent
|
gptkb:BAY_59-7939
|
|
gptkbp:bfsLayer
|
7
|